Artemisinin inhibits extracellular matrix metalloproteinase inducer (EMMPRIN) and matrix metalloproteinase-9 expression via a protein kinase Cδ/p38/extracellular signal-regulated kinase pathway in phorbol myristate acetate-induced THP-1 macrophages

Clinical and Experimental Pharmacology and Physiology

Volumn 38, Issue 1, 2011, Pages 11-18

  Wang, Yue ^a   Huang, Zhou Qing ^a   Wang, Chang Qian ^a   Wang, Lian Sheng ^a   Meng, Shu ^a   Zhang, Ya Chen ^a   Chen, Ting ^a   Fan, Yu Qi ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Artemisinin; Atherosclerosis; Extracellular matrix metalloproteinase inducer (EMMPRIN); Matrix metalloproteinase 9; Monocyte macrophage

Indexed keywords

ARTEMISININ; CD147 ANTIGEN; GELATINASE B; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN KINASE C DELTA; ROTTLERIN;

ARTEMISIA ANNUA; ARTICLE; ATHEROSCLEROTIC PLAQUE; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MACROPHAGE; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION;

ANTI-INFECTIVE AGENTS; ANTIGENS, CD147; ARTEMISININS; CELL LINE; DOWN-REGULATION; DRUG EVALUATION, PRECLINICAL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION; HUMANS; MACROPHAGES; MAP KINASE SIGNALING SYSTEM; MATRIX METALLOPROTEINASE 9; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASE C-DELTA; SIGNAL TRANSDUCTION; TETRADECANOYLPHORBOL ACETATE;

EID: 78650652371     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2010.05454.x     Document Type: Article

References (54)

1. Weber C, Zernecke A, Libby P. The multifaceted contributions of leukocyte subsets to atherosclerosis: Lessons from mouse models. Nat. Rev. Immunol. 2008; 8: 802-15.
2. Chen JW, Chen YH, Lin SJ. Long-term exposure to oxidized low-density lipoprotein enhances tumor necrosis factor-alpha-stimulated endothelial adhesiveness of monocytes by activating superoxide generation and redox-sensitive pathways. Free Radic. Biol. Med. 2006; 40: 817-26.
3. Kunte H, Amberger N, Busch MA, Rückert RI, Meiners S, Harms L. Markers of instability in high-risk carotid plaques are reduced by statins. J. Vasc. Surg. 2008; 47: 513-22.
4. Watanabe N, Ikeda U. Matrix metalloproteinases and atherosclerosis. Curr. Atheroscler. Rep. 2004; 6: 112-20.
5. Major TC, Liang L, Lu X, Rosebury W, Bocan TM. Extracellular matrix metalloproteinase inducer (EMMPRIN) is induced upon monocyte differentiation and is expressed in human atheroma. Arterioscler. Thromb. Vasc. Biol. 2002; 22: 1200-7.
6. Kai H, Ikeda H, Yasukawa H et al. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J. Am. Coll. Cardiol. 1998; 32: 368-72.
7. Blankenberg S, Rupprecht HJ, Poirier O et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003; 107: 1579-85.
8. Biswas C, Zhang Y, DeCastro R et al. The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. Cancer Res. 1995; 55: 434-9.
9. Schmidt R, Bültmann A, Ungerer M et al. Extracellular matrix metalloproteinase inducer regulates matrix metalloproteinase activity in cardiovascular cells: Implications in acute myocardial infarction. Circulation 2006; 113: 834-41.
10. Sun XZ, Li ZF, Liu Y, Fang P, Li MX. Inhibition of cGMP phosphodiesterase 5 suppresses matrix metalloproteinase-2 production in pulmonary artery smooth muscles cells. Clin. Exp. Pharmacol. Physiol. 2010; 37: 362-7.
11. Haug C, Lenz C, Díaz F, Bachem MG. Oxidized low-density lipoproteins stimulate extracellular matrix metalloproteinase inducer (EMMPRIN) release by coronary smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 2004; 24: 1823-9.
12. Schmidt R, Bültmann A, Fischel S et al. Extracellular matrix metalloproteinase inducer (CD147) is a novel receptor on platelets, activates platelets, and augments nuclear factor kappaB-dependent inflammation in monocytes. Circ. Res. 2008; 102: 302-9.
13. Meshnick SR, Taylor TE, Kamchonwongpaisan S. Artemisinin and the antimalarial endoperoxides: From herbal remedy to targeted chemotherapy. Microbiol. Rev. 1996; 60: 301-15.
14. Haynes RK. Artemisinin and derivatives: The future for malaria treatment? Curr. Opin. Infect. Dis. 2001; 14: 719-26.
15. Hou J, Wang D, Zhang R, Wang H. Experimental therapy of hepatoma with artemisinin and its derivatives. In vitro and in vivo activity, chemosensitization, and mechanisms of action. Clin. Cancer Res. 2008; 14: 5519-30.
16. Dell'Eva R, Pfeffer U, Vené R et al. Inhibition of angiogenesis in vivo and growth of Kaposi's sarcoma xenograft tumors by the anti-malarial artesunate. Biochem. Pharmacol. 2004; 68: 2359-66.
17. D'Angelo JG, Bordón C, Posner GH, Yolken R, Jones-Brando L. Artemisinin derivatives inhibit Toxoplasma gondii in vitro at multiple steps in the lytic cycle. J. Antimicrob. Chemother. 2009; 63: 146-50.
18. Wang Z, Qiu J, Guo TB et al. Anti-inflammatory properties and regulatory mechanism of a novel derivative of artemisinin in experimental autoimmune encephalomyelitis. J. Immunol. 2007; 179: 5958-65.
19. Wang JX, Tang W, Shi LP et al. Investigation of the immunosuppressive activity of artemether on T-cell activation and proliferation. Br. J. Pharmacol. 2007; 150: 652-61.
20. Huang Z, Wang L, Meng S, Wang Y, Chen T, Wang C. Berberine reduces both MMP-9 and EMMPRIN expression through prevention of p38 pathway activation in PMA-induced macrophages. Int. J. Cardiol. Epub 2 July 2009; doi:10.1016/j.ijcard.2009.06.023.
21. Huang Z, Wang C, Wei L et al. Resveratrol inhibits EMMPRIN expression via P38 and ERK1/2 pathways in PMA-induced THP-1 cells. Biochem. Biophys. Res. Commun. 2008; 374: 517-21.
22. 3. J. Leukoc. Biol. 1996; 59: 555-61.
23. Tsuchiya S, Kobayashi Y, Goto Y et al. Induction of maturation in cultured human monocytic leukemia cells by a phorbol diester. Cancer Res. 1982; 42: 1530-6.
24. Wang Y, Huang ZQ, Wang LS et al. Anti-malarial artemisinin inhibits pro-inflammatory cytokines via inhibition of NF-κB canonical signaling pathway in PMA-induced THP-1 monocytes. Int. J. Mol. Med. 2011; (in press).
25. Yang JM, Xu Z, Wu H, Zhu H, Wu X, Hait WN. Overexpression of extracellular matrix metalloproteinase inducer in multidrug resistant cancer cells. Mol. Cancer Res. 2003; 1: 420-7.
26. Yan L, Zucker S, Toole BP. Roles of the multifunctional glycoprotein, emmprin (basigin; CD147), in tumour progression. Thromb. Haemost. 2005; 93: 199-204.
27. Li R, Huang L, Guo H, Toole BP. Basigin (murine EMMPRIN) stimulates matrix metalloproteinase production by fibroblasts. J. Cell. Physiol. 2001; 186: 371-9.
28. Simon C, Goepfert H, Boyd D. Inhibition of the p38 mitogen-activated protein kinase by SB 203580 blocks PMA-induced Mr 92, 000 type IV collagenase secretion and in vitro invasion. Cancer Res. 1998; 58: 1135-9.
29. Gum R, Wang H, Lengyel E, Juarez J, Boyd D. Regulation of 92 kDa type IV collagenase expression by the jun aminoterminal kinase- and the extracellular signal-regulated kinase-dependent signaling cascades. Oncogene 1997; 14: 1481-93.
30. Kim SY, Lee EJ, Woo MS et al. Inhibition of matrix metalloproteinase-9 gene expression by an isoflavone metabolite, irisolidone in U87MG human astroglioma cells. Biochem. Biophys. Res. Commun. 2008; 66: 493-9.
31. Amemiya T, Kambe T, Fukumori R, Kubo T. Role of protein kinase C beta in phorbol ester-induced c-fos gene expression in neurons of normotensive and spontaneously hypertensive rat brains. Brain Res. 2005; 1040: 129-36.
32. Liu JF, Crépin M, Liu JM, Barritault D, Ledoux D. FGF-2 and TPA induce matrix metalloproteinase-9 secretion in MCF-7 cells through PKC activation of the Ras/ERK pathway. Biochem. Biophys. Res. Commun. 2002; 293: 1174-82.
33. Tatin F, Varon C, Génot E, Moreau V. A signalling cascade involving PKC Src and Cdc42 regulates podosome assembly in cultured endothelial cells in response to phorbol ester. J. Cell Sci. 2006; 119: 769-81.
34. Jespersen C, Doller A, Akool el S et al. Molecular mechanisms of nitric oxide-dependent inhibition of TPA-induced matrix metalloproteinase-9 (MMP-9) in MCF-7 cells. J. Cell. Physiol. 2009; 219: 276-87.
35. Gschwendt M, Muller HJ, Kielbassa K et al. Rottlerin, a novel protein kinase inhibitor. Biochem. Biophys. Res. Commun. 1994; 28: 93-8.
36. Wang J, Zhou H, Zheng J et al. The antimalarial artemisinin synergizes with antibiotics to protect against lethal live Escherichia coli challenge by decreasing proinflammatory cytokine release. Antimicrob. Agents Chemother. 2006; 50: 2420-7.
37. Xu H, He Y, Yang X et al. Anti-malarial agent artesunate inhibits TNF-alpha-induced production of proinflammatory cytokines via inhibition of NF-kappaB and PI3 kinase/Akt signal pathway in human rheumatoid arthritis fibroblast-like synoviocytes. Rheumatology 2007; 46: 920-6.
38. Fiotti N, Altamura N, Orlando C et al. Metalloproteinases-2-9 and TIMP-1 expression in stable and unstable coronary plaques undergoing PCI. Int. J. Cardiol. 2008; 127: 350-7.
39. Death AK, Fisher EJ, McGrath KC, Yue DK. High glucose alters matrix metalloproteinase expression in two key vascular cells: Potential impact on atherosclerosis in diabetes. Atherosclerosis 2003; 168: 263-9.
40. Ferroni P, Basili S, Martini F et al. Serum metalloproteinase 9 levels in patients with coronary artery disease: A novel marker of inflammation. J. Investig. Med. 2003; 51: 295-300.
41. Gough PJ, Gomez IG, Wille PT, Raines EW. Macrophage expression of active MMP-9 induces acute plaque disruption in apoE-deficient mice. J. Clin. Invest. 2006; 116: 59-69.
42. Yamamoto D, Takai S. Pharmacological implications of MMP-9 inhibition by ACE inhibitors. Curr. Med. Chem. 2009; 16: 1349-54.
43. Nagashima H, Aoka Y, Sakomura Y et al. A 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, cerivastatin, suppresses production of matrix metalloproteinase-9 in human abdominal aortic aneurysm wall. J. Vasc. Surg. 2002; 36: 158-63.
44. Kajimoto K, Miyauchi K, Kasai T et al. Short-term 20-mg atorvastatin therapy reduces key inflammatory factors including c-Jun N-terminal kinase and dendritic cells and matrix metalloproteinase expression in human abdominal aortic aneurysmal wall. Atherosclerosis 2009; 206: 505-11.
45. Langlois A, Chouinard F, Flamand N, Ferland C, Rola-Pleszczynski M, Laviolette M. Crucial implication of protein kinase C (PKC)-delta, PKC-zeta, ERK-1/2, and p38 MAPK in migration of human asthmatic eosinophils. J. Leukoc. Biol. 2009; 85: 656-63.
46. Sun J, Ramnath RD, Tamizhselvi R, Bhatia M. Role of protein kinase C and phosphoinositide 3-kinase-Akt in substance P-induced proinflammatory pathways in mouse macrophages. FASEB J. 2009; 23: 997-1010.
47. Palaniyandi SS, Sun L, Ferreira JC, Mochly-Rosen D. Protein kinase C in heart failure: A therapeutic target? Cardiovasc. Res. 2009; 82: 229-39.
48. Lee MC, Wei SC, Tsai-Wu JJ, Wu CH, Tsao PN. Novel PKC signaling is required for LPS-induced soluble Flt-1 expression in macrophages. J. Leukoc. Biol. 2008; 84: 835-41.
49. Kontny E, Kurowska M, Szczepañska K, Maœliñski W. Rottlerin, a PKC isozyme-selective inhibitor, affects signaling events and cytokine production in human monocytes. J. Leukoc. Biol. 2000; 67: 249-58.
50. Park SK, Hwang YS, Park KK, Park HJ, Seo JY, Chung WY. Kalopanaxsaponin A inhibits PMA-induced invasion by reducing matrix metalloproteinase-9 via PI3K/Akt- and PKCdelta-mediated signaling in MCF-7 human breast cancer cells. Carcinogenesis 2009; 30: 1225-33.
51. Rahman A, Anwar KN, Uddin S et al. Protein kinase C-delta regulates thrombin-induced ICAM-1 gene expression in endothelial cells via activation of p38 mitogen-activated protein kinase. Mol. Cell. Biol. 2001; 21: 5554-65.
52. Shaw EE, Wood P, Kulpa J, Yang FH, Summerlee AJ, Pyle WG. Relaxin alters cardiac myofilament function through a PKC-dependent pathway. Am. J. Physiol. Heart Circ. Physiol. 2009; 297: H29-36.
53. Tanaka Y, Gavrielides MV, Mitsuuchi Y, Fujii T, Kazanietz MG. Protein kinase C promotes apoptosis in LNCaP prostate cancer cells through activation of p38 MAPK and inhibition of the Akt survival pathway. J. Biol. Chem. 2003; 278: 33753-62.
54. Ramnath RD, Sun J, Adhikari S, Zhi L, Bhatia M. Role of PKC-delta on substance P-induced chemokine synthesis in pancreatic acinar cells. Am. J. Physiol. Cell Physiol. 2008; 294: C683-92.